Clinical Trials Browser

Bone Marrow Failure Disorders, Cytopenia, Bone Diseases, Bone Diseases, Developmental, Bone Marrow Diseases, Graft vs Host Disease, Hematologic Diseases, Hemoglobinopathies, Immunologic Deficiency Syndromes, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Leukocyte Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Musculoskeletal Diseases, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Osteochondrodysplasias, Osteopetrosis, Osteosclerosis, Pancytopenia, Precancerous Conditions, Preleukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Genetic Diseases, Inborn, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02624570 2020-07-15

AMLFLT3

No longer available

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03723057 2019-10-24

Expanded Access for AG-221

No longer available

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03114228 2019-10-15

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

No longer available

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02197650 2018-12-04

EAP

No longer available

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03409081 2018-09-13

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

No longer available

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00423826 2016-02-29

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No longer available

LymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cellSarcoma

Congenital Abnormalities, Immunoglobulin Light-chain Amyloidosis, Blast Crisis, Burkitt Lymphoma, Leukemia, Erythroblastic, Acute, Hodgkin Disease, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Myelodysplastic Syndromes, Precancerous Conditions, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT01549548 2013-03-15

Compassionate Use Ponatinib

No longer available

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00302016 2011-08-26

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

No longer available

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00413270 2011-07-13

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

No longer available

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Clinical Trials

Expanded Access to ABBV-787

EMTP

Expanded Access Program for Revumenib

Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Managed Access Programs for PKC412, Midostaurin

Expanded Access to Navitoclax

Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Nilotinib, for Patients With CML-CP or CML-AP

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Flotetuzumab Expanded Access Program

Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant

AMLFLT3

Expanded Access for AG-221

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

EAP

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Compassionate Use Ponatinib

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant